YU25500A - Postupak za sintezu analoga nukleozida - Google Patents

Postupak za sintezu analoga nukleozida

Info

Publication number
YU25500A
YU25500A YU25500A YUP25500A YU25500A YU 25500 A YU25500 A YU 25500A YU 25500 A YU25500 A YU 25500A YU P25500 A YUP25500 A YU P25500A YU 25500 A YU25500 A YU 25500A
Authority
YU
Yugoslavia
Prior art keywords
nucleosite
synthesis
analogues
protected
heterocycluse
Prior art date
Application number
YU25500A
Other languages
English (en)
Inventor
Robert William Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU25500A publication Critical patent/YU25500A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na unapredjenje metoda za sintezu nukleozida sa niskim odnosom α:Гџ anomera. Metod sadrži spajanje zaštićenog furanozil halida i odgovarajućeg zaštićenog heterociklusa u prisustvu nukleofilnog polarnog rastvarača i jake baze.[The invention refers to the improvement of the method for nucleosite synthesis with the low ratio of L- B anomeres. Method contents connecting protected furanozile halide and suitable protected heterocycluse in the presence of nucleofile polar solvent and strong base.
YU25500A 1999-05-11 2000-05-03 Postupak za sintezu analoga nukleozida YU25500A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13365199P 1999-05-11 1999-05-11

Publications (1)

Publication Number Publication Date
YU25500A true YU25500A (sh) 2003-08-29

Family

ID=22459680

Family Applications (1)

Application Number Title Priority Date Filing Date
YU25500A YU25500A (sh) 1999-05-11 2000-05-03 Postupak za sintezu analoga nukleozida

Country Status (22)

Country Link
US (1) US6271370B1 (sh)
EP (1) EP1052264B1 (sh)
JP (1) JP2001011092A (sh)
KR (1) KR100403900B1 (sh)
CN (1) CN1275575A (sh)
AR (1) AR028991A1 (sh)
AT (1) ATE291582T1 (sh)
AU (1) AU3401100A (sh)
BR (1) BR0002089A (sh)
CA (1) CA2307951A1 (sh)
CZ (1) CZ20001710A3 (sh)
DE (1) DE60018833D1 (sh)
HU (1) HUP0001843A3 (sh)
ID (1) ID25992A (sh)
IL (1) IL136027A0 (sh)
IN (1) IN186850B (sh)
MX (1) MXPA00004532A (sh)
PL (1) PL340109A1 (sh)
RU (1) RU2200738C2 (sh)
TR (1) TR200001340A2 (sh)
YU (1) YU25500A (sh)
ZA (1) ZA200002263B (sh)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
ATE541848T1 (de) * 2005-05-05 2012-02-15 Ardea Biosciences Inc Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006277769B2 (en) 2005-08-08 2011-06-02 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
WO2009079412A2 (en) 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors
PL2229358T3 (pl) 2007-12-14 2011-09-30 Pulmagen Therapeutics Asthma Ltd Związki indolowe i ich zastosowanie terapeutyczne
CA2711637A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
EA201190119A1 (ru) 2009-02-17 2012-05-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
US8927513B2 (en) * 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
NZ620020A (en) 2009-08-17 2015-06-26 Intellikine Llc Heterocyclic compounds and uses thereof
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
KR20140077916A (ko) 2011-09-15 2014-06-24 노파르티스 아게 티로신 키나제로서의 6-치환된 3-(퀴놀린-6-일티오)-[1,2,4]트리아졸로[4,3-a]피라딘
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
WO2013083606A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2013083604A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
KR20140103925A (ko) 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP3255049A1 (en) 2012-06-29 2017-12-13 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
US9181242B2 (en) 2013-06-06 2015-11-10 Chiesi Farmaceutici S.P.A. Kinase inhibitors
AU2014317600A1 (en) 2013-09-05 2016-03-03 F.Hoffmann-La Roche Ag Triazolopyridine compounds, compositions and methods of use thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
JP2018507236A (ja) 2015-03-04 2018-03-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トリアゾロピリジン化合物及びその使用法
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
EP3394060A1 (en) 2015-12-23 2018-10-31 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urea derivatives and their use as p38 mapk inhibitors
AR107163A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
EP3452464B1 (en) 2016-05-05 2021-12-15 F. Hoffmann-La Roche AG Pyrazole derivatives, compositions and therapeutic use thereof
CA3035712A1 (en) 2016-09-06 2018-03-15 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
BR112019013287A2 (pt) 2016-12-29 2019-12-24 Hoffmann La Roche compostos de pirazolopirimidina e métodos de uso dos mesmos
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
JP7256757B2 (ja) 2017-05-22 2023-04-12 エフ. ホフマン-ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
EP3630767A1 (en) 2017-05-22 2020-04-08 H. Hoffnabb-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
EP3740488A1 (en) 2018-01-15 2020-11-25 F. Hoffmann-La Roche AG Pyrazolopyrimidine compounds as jak inhibitors
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
JP2022537964A (ja) 2019-06-18 2022-08-31 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Jakキナーゼのピラゾロピリミジンスルホン阻害剤およびその使用
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207400A (ja) * 1985-03-11 1986-09-13 Nippon Zoki Pharmaceut Co Ltd ヌクレオシド化合物の製造方法
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4859677A (en) 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5246931A (en) 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5470857A (en) 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
WO1996004293A1 (fr) * 1994-08-02 1996-02-15 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazoles antitumoraux
US5659023A (en) 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
KR19990081940A (ko) 1996-01-23 1999-11-15 그레이엄 브레레톤, 레슬리 에드워즈 항바이러스제로서 변형된 벤즈이미다졸 누클레오시드

Also Published As

Publication number Publication date
PL340109A1 (en) 2000-11-20
ID25992A (id) 2000-11-16
HUP0001843A3 (en) 2001-09-28
MXPA00004532A (es) 2002-03-08
KR100403900B1 (ko) 2003-11-01
HU0001843D0 (en) 2000-07-28
DE60018833D1 (de) 2005-04-28
AU3401100A (en) 2000-11-16
ZA200002263B (en) 2001-12-24
KR20010069193A (ko) 2001-07-23
CA2307951A1 (en) 2000-11-11
CZ20001710A3 (cs) 2001-09-12
IN186850B (sh) 2001-11-24
EP1052264A3 (en) 2001-06-13
CN1275575A (zh) 2000-12-06
HUP0001843A2 (hu) 2001-06-28
EP1052264B1 (en) 2005-03-23
TR200001340A2 (tr) 2000-12-21
BR0002089A (pt) 2001-01-02
ATE291582T1 (de) 2005-04-15
US6271370B1 (en) 2001-08-07
RU2200738C2 (ru) 2003-03-20
IL136027A0 (en) 2001-05-20
AR028991A1 (es) 2003-06-04
JP2001011092A (ja) 2001-01-16
EP1052264A2 (en) 2000-11-15

Similar Documents

Publication Publication Date Title
YU25500A (sh) Postupak za sintezu analoga nukleozida
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
HUP0200297A3 (en) Method for acylating peptides and the glutaminic acid derivatives as acylating agents
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
TW437388U (en) Structure of universal, horizontal, electrical transportation vehicle
AU2001245928A1 (en) Electrolyzer and method of using the same
MY134559A (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
IL130102A (en) Aminoguanidines and alkoxyguanidines as protease inhibitors, pharmaceutical compositions containing the same and processes for preparing the same
WO2005051358A8 (en) Composition and method for enhancing bioavailability
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
IL148803A0 (en) Novel composition and method for stabilizing the same
MY122278A (en) 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
AU3885301A (en) Anti-mycobacterium compositions and methods of preparing and using same
GB0015426D0 (en) Method for generating soluble highly multimeric proteins
AU5956001A (en) Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
AU2002218075A1 (en) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
AU4859200A (en) Process for enhancing the value of hydrocarbonaceous natural resources
WO2004092727A3 (en) Compound libraries and methods for drug discovery
GR20010100601A (el) Προτυπα αναφορας για τον προσδιορισμο της καθαροτητας ή σταθεροτητας της μιλεινικης αμλοδιπινης και διεργασιες για αυτα.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU2002349522A1 (en) Composition for electrolytic solution and process for producing the same
ID27440A (id) Proses untuk menyiapkan penengah-penengah
ZA200000578B (en) Process for the preparation of organic azides.
AU4242301A (en) Method for producing amines by the hydroaminomethylation of olefins in the presence of ionic liquids
AU1024101A (en) N-substituted perfluoroalkylated pyrrolidines, process for making them and process for the addition of rf-iodide to an olefin